美女免费一级视频在线观看
BGB Group announced this week that it has hired David Coman to serve as CEO and lead the healthcare commercialization and communications company into its next era.
According to Coman, he is eager to helm the 2024 MM+M Agency 100 honoree and make an impact in the healthcare commercialization industry using precision, data and solutions.
Coman joins the BGB Group with extensive experience in the analytics space, having previously leveraged data and technology to drive insights and solutions at previous organizations.
He most recently served as CEO of Science 37, a pioneer in decentralized clinical trials. Coman said he is most enthusiastic about working with the BGB Group team to create actionable solutions for the clients across the healthcare and pharmaceutical industry.
Per its Agency 100 profile, BGB Group serves bluechip pharma clients like Eisai, Bristol Myers Squibb, Affimed and Gilead Oncology.
“In the very short time I’ve been here, I’ve been blown away by the talent at BGB,” said Coman. “The company has done a great job in growing, expanding and innovating over the last several years.”
Founded in 2005, BGB Group has focused its efforts on offering healthcare commercialization and consulting services to enhance products and services across the industry.
During that time, company founders Greg Passaretti and Brendon Phalen have expanded the firm to establish offices in New York, Washington, D.C., Boston and London.
A few years ago, the company received a boost, too.
In 2021, BGB partnered with TPG, a global alternative asset management firm, to continue its expansion with strategic partnerships and acquisitions. This included a renewed focus on the medical communications advertising space and honing in on providing accurate data and analytic services.
As a seasoned professional with nearly two decades of experience in the pharmaceutical industry, Coman is tasked with using his skills to enhance data insights for clients and develop high-impact campaigns for healthcare professionals.
More notably, he is passionate about being able to continue to create access to effective pharmaceutical products and services.
“I’m excited about making a difference. When you think about what we’re trying to do everyday, one is to make healthier people, and I think we have the opportunity to get the right drugs into the hands of people who need it the most.” said Coman.
The pharmaceutical industry is at a pivotal moment of change, and the arrival of the second Trump administration in January could usher in more regulations and impact the way companies run.
Coman acknowledged that while there are several headwinds facing pharma currently, he is focused on ensuring that new innovations in the industry create an impact.
“Science grows in a lot of places — not just medical science but data science and creative science,” said Coman. “I look at that as an amazing core in which we can grow in a market that is expansive. Change comes with opportunities for us to grow.”
Additionally, BGB Group has been taking steps to expand their portfolio of creativity and approach to solutions for clients.
Earlier this summer, the agency appointed Chris Palmer as its creative chief, who told MM+M how passionate he is about leveraging AI to enhance solutions for consumers.
With all the potential looming changes in the industry, Coman is confident that BGB Group will be able to steer clients into the right direction.
“BGB has an incredible set of creative and consulting services, and I know this will be an asset when navigating clients through changes across the industry,” said Coman.